Outcome Comparison of Allograft and Synthetic Bone Substitute in High Tibial Osteotomy

October 13, 2014 updated by: Tae Kyun Kim, Seoul National University Hospital

Outcome Comparison of Allogenic Cancellous Bone and a New Synthetic Bone Substitute (geneX®) in Filling the Bone Defect Created With Medial Open Wedge High Tibial Osteotomy

This study is conducted to determine whether a new synthetic bone substitute is better than allogenic bone graft for addressing bone defect in medial open wedge high tibial osteotomy in terms of postoperative pain, postoperative bleeding, operation time and bone healing. The investigators hypothesized the new synthetic bone substitute would bring better outcomes in the outcome variables mentioned above.

Study Overview

Detailed Description

High tibial osteotomy is a well-established treatment option for the young patients (aged 40~55years) with knee osteoarthritis which is confined in medial compartment of the knee. Classical technique was lateral closing wedge osteotomy, but recently medial open wedge osteotomy has gained popularity with the advent of new fixation devices and refined surgical techniques. The surgeon can correct the deformity more precisely in both coronal and sagittal planes simultaneously with medial opening technique. And it can avoid complications associated with lateral closing technique like tibial shaft offset or peroneal nerve palsy. But medial opening technique inevitably creates large bone defect, which has to be addressed to avoid complications like loss of correction or delayed/non-union. Autologous bone is widely accepted as a standard for filling bone defects, but its supply is limited and harvesting autologous bone adds to surgical morbidity like bleeding, pain or fracture at the donor site. Therefore, there has been much effort to find materials to substitute autologous bone. Many studies reported the results of using allogenic bone for addressing bone defects and most of them showed favorable results. But some allogenic bone products are cumbersome to process to make it fit to the defect, and there are potential risk of disease transmission, if the products are not properly treated. Bone cements of several different composition has been developed and when used for filling bone defect, they also showed good results in general. Recently, a new synthetic bone substitute based on calcium phosphate and calcium sulfate (geneX®, Biocomposites Co.,Ltd.) has been introduced and is commercially available. While providing initial mechanical strength, its calcium sulfate component is rapidly absorbed to provide space for new bone ingrowth and its surface is made to negatively charged, which helps accelerate new bone formation. It is provided as an injectable paste, which is easier to handle than allogenic bone, so it may help reduce operation time. With these theoretical advantages, there are some anecdotal reports that patients treated with geneX® presented less postoperative pain and bleeding than patients treated with allogenic bone graft. Therefore, we conducted this study to determine whether the new synthetic bone substitute (geneX®) is better than allogenic bone for addressing bone defect created in medial open wedge high tibial osteotomy.

Study Type

Interventional

Enrollment (Anticipated)

60

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Gyeonggi-do
      • Seongnam-Si, Gyeonggi-do, Korea, Republic of, 463-707
        • Recruiting
        • Joint Reconstruction Center, Seoul National University Bundang Hospital
        • Contact:
          • Tae Kyun Kim, MD, PhD
          • Phone Number: 82-31-787-7196
          • Email: osktk@snubh.org

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosis of primary osteoarthritis of the knee which is confined to medial compartment
  • Scheduled for high tibial osteotomy
  • Written signed consent available

Exclusion Criteria:

  • Patients who refuse to participate in the study
  • Previous history of major orthopedic surgery around the operating knee
  • Congenital anomaly involving proximal tibia
  • Revision high tibial osteotomy
  • Patients who is receiving another major knee surgery simultaneously with high tibial osteotomy at the same knee

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Allogenic bone graft group
Patients in this arm is treated with allogenic bone graft to fill the bone defect created with medial open wedge high tibial osteotomy
Patients in this arm is treated with allogenic bone graft to fill the bone defect created with medial open wedge high tibial osteotomy
Experimental: Synthetic bone substitute (geneX®) group
Patients in this arm is treated with synthetic bone substitute(geneX®) to fill the bone defect created with medial open wedge high tibial osteotomy
Patients in this arm is treated with synthetic bone substitute (geneX®) to fill the bone defect created with medial open wedge high tibial osteotomy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Temporal change of postoperative pain
Time Frame: from 2 days after surgery to 12 months after surgery

Pain on operation site is measured on a 0-to-10 visual analogue scale(VAS) and 5-point Likert scale (0.no pain, 1.slight pain, 2.moderate pain, 3.severe pain, 4.extreme pain).

Initial postoperative pain will be recorded on postoperative day 2. After discharge from hospital (on postoperative day 2, on average), patients will visit outpatient department on 2weeks, 6weeks, 3months, 6months, 12months after surgery and pain measurements on each visit will be recorded.

from 2 days after surgery to 12 months after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pre&postoperative Hemoglobin level
Time Frame: on admission (preop.), postoperative day 2 (postop.)
Preoperative hemoglobin level is measured when the patient is admitted to the hospital for surgery and postoperative level is measured on postoperative day 2. The differences between values will be calculated.
on admission (preop.), postoperative day 2 (postop.)
Total operation time
Time Frame: from skin incision to deflation of tourniquet
Total operation time is defined as the time interval between skin incision and deflation of tourniquet (thigh tourniquet used in the operation to provide bloodless surgical field). Measured in minutes.
from skin incision to deflation of tourniquet
Temporal change of weight bearing status
Time Frame: from 2 weeks after surgery to 12 months after surgery

As a proxy variable of bone healing status, whether the patient can bear weight on operated knee is measured on a 3 point scale (1.full weight bearing, 2.partial weight bearing, 3.no weight bearing)

Patients will visit outpatient department on 2weeks, 6weeks, 3months, 6months, 12months after surgery and weight bearing status on each visit will be recorded.

from 2 weeks after surgery to 12 months after surgery
Temporal change of pain with weight bearing
Time Frame: from 2 weeks after surgery to 12 months after surgery

As a proxy variable of bone healing status, pain with weight bearing is measured on a 0-to-10 visual analogue scale(VAS) and 5-point Likert scale (0.no pain, 1.slight pain, 2.moderate pain, 3.severe pain, 4.extreme pain)

Patients will visit outpatient department on 2weeks, 6weeks, 3months, 6months, 12months after surgery and pain with weight bearing on each visit will be recorded.

from 2 weeks after surgery to 12 months after surgery
Amount of drainage
Time Frame: from the end of surgery until drain removal, which is anticipated on postoperative day 1 or 2
Total amount of drainage (in milliliters) from indwelling drain located in operative site, until its removal.
from the end of surgery until drain removal, which is anticipated on postoperative day 1 or 2
Working time for bone defect filling
Time Frame: from the start of processing allograft or synthetic bone substitute to finish filling bone defect
Time required to fill the bone defect (from the start of processing either allogenic bone graft or synthetic bone substitute to completely finish filling the defect. Measured in seconds.
from the start of processing allograft or synthetic bone substitute to finish filling bone defect
Temporal progression of bone healing on X-rays
Time Frame: from 3 months after surgery to 12months after surgery

Two independent investigators assess the progression of bone healing status on X-rays and the agreement between investigators will be measured. Bone healing status is assessed based on 3 point scale. (1. union not achieved yet, 2. partial union achieved, 3. complete union achieved)

Patients will visit outpatient department on 2weeks, 6weeks, 3months, 6months, 12months after surgery and bone healing status on X-rays will be recorded on 3months, 6months and 12months after surgery.

from 3 months after surgery to 12months after surgery

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Amount of transfusion
Time Frame: from the start of operation until discharge of the patient from hospital (which is anticipated on postoperative day 2 on average)
Amount of transfusion during patient's hospital stay, if any, is measured in packs.
from the start of operation until discharge of the patient from hospital (which is anticipated on postoperative day 2 on average)
Postoperative complications
Time Frame: from the date of operation to the date of occurence of any complications, assessed up to 12 months after surgery
When an event of postoperative complication occurs, it is recorded with postoperative date.
from the date of operation to the date of occurence of any complications, assessed up to 12 months after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Tae Kyun Kim, MD, PhD, Joint Reconstruction Center, Seoul National University Bundang Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2013

Primary Completion (Anticipated)

November 1, 2015

Study Completion (Anticipated)

January 1, 2016

Study Registration Dates

First Submitted

November 11, 2013

First Submitted That Met QC Criteria

November 26, 2013

First Posted (Estimate)

December 4, 2013

Study Record Updates

Last Update Posted (Estimate)

October 15, 2014

Last Update Submitted That Met QC Criteria

October 13, 2014

Last Verified

October 1, 2014

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteoarthritis, Knee

Clinical Trials on Allogenic bone graft

3
Subscribe